In brief
  • Compounded GLP-1 copies face FDA letters now that shortages declared from 2022 have closed
  • FTC TruHeight case and $150,000 NextMed order target unsupported weight-loss marketing
  • Readers can compare approval status, salt form, added ingredients and measured dose

Patent protection keeps generic semaglutide from sale until at least 2032, while tirzepatide patents extend to 2036, and regulators had permitted compounding of GLP-1 medicines during severe shortages that started in 2022. Those shortage listings have now closed, and Stanford Medicine reports that the FDA has started sending warning letters to some compounding pharmacies about unsupported statements for compounded copies. The FTC shows a matter titled TruHeight, In the Matter of, dated July 15, 2026, among health claims cases.

GLP-1 means glucagon-like peptide-1, a gut hormone involved in blood sugar and appetite regulation. Medicines that act on its receptor copy that signal. Semaglutide brands include Ozempic, Wegovy and Rybelsus, and tirzepatide brands include Mounjaro and Zepbound.

Copies made by compounders lack FDA approval held by brand-name medicines. During the peak in 2024, almost 1 in 3 Americans using a GLP-1 drug reported supply from a compounding pharmacy. Patented GLP-1 products carry list prices above $1,000 per month, and clinicians report that price and access pressures pushing buyers toward compounded copies are genuine.

Formula records often show quiet substitutions. Some compounders list salt forms like semaglutide sodium, which FDA has not approved and which have not been shown safe and effective in people. Many list added vitamin B12 plus other parts such as B6, niacinamide, glycine or carnitine that have no proven benefit for weight loss or diabetes management. A 2026 study found that tirzepatide mixed with B12 can join chemically, creating a new molecule absent from the FDA-approved medicine, a result Eli Lilly also reproduced.

Measured dose creates further uncertainty. The FDA has described cases where patients drawing from multidose vials took 10 to 20 times the prescribed quantity in error. Some compounding pharmacies offer sublingual drops or dissolving tablets with semaglutide or tirzepatide that clinical trials never examined. Poison control centers in the U.S. have recorded a more than 15-fold increase in calls tied to injected weight-loss drugs since 2019.

The FTC approved a final order against telehealth seller NextMed and principals Robert Epstein and Frank Leonardo concerning GLP-1 weight-loss programs. In its July 2025 complaint the FTC alleged NextMed marketed weight-loss programs with hidden costs, unsupported weight-loss statements, false testimonials and altered reviews. The final order orders payment of $150,000, expected to be used for consumer refunds, and calls for competent and reliable evidence behind statements about average or typical results.

Marina Basina, MD, clinical professor in endocrinology, gerontology and metabolism, said the use of compounded drugs in patients using GLP 1s without medical supervision poses significant risk and can bring significant consequences.

Written by

Holly Rasmussen

Holly looks after the brands Seed to Capsule works with and makes sure every sponsored page is marked as one. She spent five years buying raw materials for a natural foods retailer in Colorado, which is where she learned to ask for the paperwork first.

More from Holly Rasmussen →